Emiplacel clinical trials
Also written PLX-PAD.
How each study uses emiplacel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PLX-PAD
- 6
Studies by the year they started
6 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Pluristem Ltd. (5) · United Therapeutics (1)
Studies
Open first, then newest update. How each study uses emiplacel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for RevascularizationCompletedPhase 3Pluristem Ltd.NCT03006770Written as PLX-PAD
- Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19TerminatedPhase 2Pluristem Ltd.NCT04389450Written as PLX-PAD
- Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19TerminatedPhase 2Pluristem Ltd.NCT04614025Written as PLX-PAD
- Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)CompletedPhase 3Pluristem Ltd.NCT03451916Written as PLX-PAD
- Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)TerminatedPhase 1United TherapeuticsNCT01795950Written as PLX-PAD
- Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)CompletedPhase 1Pluristem Ltd.NCT00951210Written as PLX-PAD
Codes
What other systems call emiplacel · ClinicalTrials.gg INT016354
- UNII (FDA) DPX6XLD4X1EMIPLACELOne source FDA
- NCI Thesaurus C169942EmiplacelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DPX6XLD4X1 | EMIPLACEL | One source FDA |
| NCI Thesaurus | C169942 | Emiplacel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.